Incoming SNMMI President Alan Packard said he will focus on improving SNMMI membership value, enhancing the Journal of Nuclear Medicine's value and visibility, and addressing reimbursement issues. Although the COVID-19 pandemic has caused molybdenum-99 accessibility problems and reduced nuclear medicine-based procedure volumes, the growth of theranostics offers an opportunity for nuclear medicine to expand treatment, and SNMMI can help boost the visibility of theranostics through physician, oncologist and patient education, Packard said.
Incoming SNMMI president details leadership priorities
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.